AB1129 A SYSTEMATIC REVIEW ON PREVALENCE OF BACK PAIN AND SPONDYLOARTHRITIS BASED ON COPCORD STUDIES
Objectives: To determine, through a systematic review and meta-analysis, the prevalence of back pain (BP) and spondyloarthritis (SpA) in the adult general population and explore the heterogeneity between studies in and out Latin America (LATAM). Methods: MEDLINE, Embase, BIREME, LILLACS and Web of Science were searched using a strategy combining key words and related database-specific subject terms to identify relevant cross-sectional studies based on COPCORD methodology published since 2006. Included articles were assessed for risk of bias and quality based on the STROBE statement. Prevalence figures for BP and SpA (European Spondyloarthropathy Study Group criteria) were analyzed according to female percentage of sampled individuals, mean age and sample size. A mixed effect model was used to obtain the combined prevalence and a meta-regression to estimate the effects of these variables. Prevalence stratified values were obtained according to its geographical location. Results: 44 out of 127 papers in English, Spanish or Portuguese were selected. Of them, 16 contained BP or SpA prevalence data. Estimates for any Spa prevalence ranged from 0,1% to 2%, with an average of 0,3% (95% CI: 0,01%>0,05%). The random-effects pooled prevalence was 0,18% (0,06%>0,36%). The prevalence of BP was 6.54% (3.8%>9.2%) with a pooled value of 5.24% (2.6%>8.7%). In both cases the heterogeneity was significant (p<0.01). No effect was associated to SpA heterogeneity, but an increase in the prevalence of BP was associated to sample size (random effect coefficient: 0,045, p=0.04). The stratified analysis did not show differences in terms of heterogeneity or prevalence for BP (Pooled prevalence for BP: 5.4%; 2.9%>8.5%, p=0.9); on the contrary, for Spa, for non-LATAM studies, the pooled proportion was significant bigger (prevalence in LATAM 0.05%, 0.01%>0.012%; non-LATAM: 0.35%, 0.09%>0.78%, p=0.03)
Conclusions:
We found significant variations in prevalence across this review. In particular, they related to sample size of BP studies. Similarly, there was a significant variation between LATAM versus other latitudes respect to the prevalence of SpA. The limited number of studies included in this meta-analysis however, prevents clear explanations of the mechanisms underlying these results. Background: The most frequent manifestation of arterial thrombosis in patients affected by Antiphospholipid syndrome (APS) is ischaemic stroke, especially in young adults (less than 50 years old) [1] . Young adults affected by APS are a group of patients at greater risk of developing serious stroke events and recurrences of thrombosis. Therefore, risk stratification in this particular group is crucial, especially in order to prevent a recurrence of ischaemic thrombotic event.
Objectives: With the present study we aimed to assess the clinical usefulness of the adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) [3] for risk stratification of thrombosis relapse and/or progression of known ischaemic lesions dectected with Magnetic Resonance Imaging (MRI) in a cohort of young adult APS patients.
Methods: The analysis included 80 APS patients (≤50 years old) who presented a previous stroke event (patients who experienced cerebral venous sinus thrombosis were not included in the analysis). Clinical and laboratory data were retrospectively collected. Treatment was based on phisician's opinion according to clinical settings. The aGAPSS was calculated for each patient by adding the points corresponding to the risk factors, based on a linear transformation derived from the β regression coefficient as follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for antiβ2glycoprotein I IgG/IgM and 4 for LA. Relapse was defined as the recurrence of thrombotic event and/or progression of known ischaemic lesions detected with MRI. Results: Results pointed out that patients with relapse of thrombotic events and/or progression of known ischaemic lesions were 39 out of 80 (48.7%) and patients without relapse were 41 out of 80 (51.3%). Significantly higher aGAPSS values were observed in relapse group when compared to the non-relapse group [mean aGAPSS 9.08 (S.D. 4.7) Vs. mean aGAPSS 7.22 (S.D. 3.3); T test: p<0.05]. Distribution of aGAPPS values among the two groups is illustrated in Graph 1.
Our analysis suggests that aGAPSS could represent an effective tool to stratify the risk of relapse of thrombosis and/or progression of ischaemic lesions in young APS patients with clinical history of stroke. These data could also aid developing different therapeutic approaches, especially for patients at higher risk of relapse. Background: Obesity is a risk factor for many chronic rheumatic diseases. In rheumatoid arthritis (RA), obesity is associated with increased comorbidities, higher medical costs, disease activity, and poorer physical function 1 . In OA, obesity is a risk factor for both incidence and progression, and has a negative impact on outcomes 2 . In systemic lupus erythematous (SLE), obesity is associated with more severe renal involvement, lower quality of life, and increased cardiovascular risk 3 . Objectives: To assess associations of obesity with patient self-report multidimensional health assessment questionnaire (MDHAQ) scores and physician global assessments in patients with RA, OA and SLE seen in routine care. Methods: All patients at one academic center complete a MDHAQ, which includes a 0-10 scale for physical function (FN), 0-10 visual analogue scales (VAS) for pain (PN) and patient global assessment (PATGL), compiled into a 0-30 RAPID3, as well as scales for fatigue, depression, and demographic data. Physicians complete a VAS for patient global (DOCGL). Body Mass Index (BMI) was calculated from the medical record as weight (kg)/ height (meters) 2 . Patients were classified by BMI as normal (18.5-25), overweight (25-30), or obese (>30) according to the WHO guidelines. Demographic and clinical MDHAQ data were compared in the 3 diagnostic groups according to BMI groups using ANOVA and chi-square tests. Results: 396 patients with RA, 425 with OA, and 306 with SLE were studied. Obesity was reported by 40% of RA and SLE patients, and 59% of OA patients, a higher percentage than matched individuals in the general population in the same region (30.8%). Obesity was higher in African-American patients (48% in RA, 70% in OA, and 53% in SLE). Education level, gender, and age did not differ significantly across the groups. Obesity was associated with poorer physical function, poorer patient global and higher pain in all 3 diagnostic groups, with higher depression scores in OA and SLE (Table) . DOCGL was significantly higher only in OA (data not shown). 
